Novadip Biosciences Secures FDA RMAT Designation for NVD003 in Rare Pediatric Bone Disorder

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, announces that the FDA has granted the Regenerative...

June 24, 2025 | Tuesday | News
Nutriband and Kindeva Complete Commercial Manufacturing Scale-Up for AVERSA™ Fentanyl, Advancing World’s First Abuse-Deterrent Opioid Patch

Nutriband Inc.  a company engaged in the development of prescription transdermal pharmaceutical products, announced that it has completed commercial...

June 24, 2025 | Tuesday | News
Harbour BioMed and Otsuka Enter $670M+ Global Agreement Across Asia, US, and Europe to Advance Bispecific T-Cell Engager for Autoimmune Diseases

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology ...

June 23, 2025 | Monday | News
PharmaJet and Immuno Cure Partner to Advance Needle-Free HIV Therapeutic DNA Vaccine with Tropis® ID System

Agreement builds on PharmaJet’s strategy to be the best-in-class delivery system for novel DNA- and RNA-based vaccines and immunotherapies usin...

June 20, 2025 | Friday | News
Neurona Therapeutics Doses First Patient in Bilateral MTLE Trial of Regenerative Cell Therapy NRTX-1001

First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - - Trial funded...

June 19, 2025 | Thursday | News
BioAegis Therapeutics’ rhu-pGSN Receives FDA Fast Track Designation for ARDS, Advancing Development of Novel Immune Modulator

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel imm...

June 18, 2025 | Wednesday | News
Innovent Doses First Patient in Phase 3 Trial of Mazdutide for Obstructive Sleep Apnea and Obesity in China

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality me...

June 16, 2025 | Monday | News
Genmab’s Epcoritamab-R-ICE Combo Shows 87% Response Rate in High-Risk Relapsed DLBCL Patients Eligible for Stem Cell Transplant

Genmab A/S announced new results from the Phase 1b/2 EPCORE® NHL-2 trial Arm 10 (NCT04663347), evaluating epcoritamab, a T-cell engaging bispeci...

June 16, 2025 | Monday | News
Dupixent Surpasses Xolair in Landmark Head-to-Head Respiratory Trial, Showing Superiority Across CRSwNP and Asthma Endpoints

New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-rel...

June 16, 2025 | Monday | News
BioAegis Advances Phase 2 Study of rhu-pGSN to Combat Decompression Sickness in SCUBA Divers

Phase 2 proof-of-concept study for rhu-pGSN, a promising intervention across a spectrum of inflammatory diseases, to be studied as an intervention for th...

June 12, 2025 | Thursday | News
Kelun-Biotech’s TROP2 ADC-Immunotherapy Combo Granted Breakthrough Therapy Designation in China for First-Line NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumo...

June 11, 2025 | Wednesday | News
EDETEK Partners with Capgemini to Accelerate AI-Driven Digital Transformation in Clinical Development

  EDETEK Inc., a global provider of leading AI-driven clinical development platforms and services, has engaged Capgemini to support its ongoing advan...

June 11, 2025 | Wednesday | News
HepaRegeniX Doses First Patient in Phase Ib Trial of HRX-215 for Liver Regeneration After Colorectal Cancer Surgery

HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, announced that...

June 11, 2025 | Wednesday | News
SynaptixBio Advances First Clinical Candidate for Rare H-ABC Disease With Promising Antisense Oligonucleotide Therapy

SynaptixBio, the only company licensed to commercialise a treatment for a rare, deadly disease, says the drug could halt disease progression and even rever...

June 11, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close